1.Pilot Study of Erlotinib to Treat NSCLC (Posted: 06/07/2005, Updated: 10/01/2007) - In this study, researchers hope to identify tumor characteristics associated with responses to treatment with the drug erlotinib that may be predictors of a survival advantage. The study will also test erlotinib as a first-line therapy for advanced NSCLC.
2.Adjuvant Treatment for Resected Lung Cancer (Posted: 08/07/2007) - In this clinical trial, doctors are exploring whether the addition of bevacizumab to adjuvant chemotherapy can help patients with early non-small cell lung cancer (NSCLC) live longer following surgery to remove their tumors.
3.Treating Lung Cancer in Nonsmokers and Former Light Smokers (Posted: 01/09/2007) - In this trial, previously untreated non-small cell lung cancer patients who never smoked or are former light smokers will be treated with either erlotinib alone or erlotinib in combination with the drugs carboplatin and paclitaxel.
4.Gene Therapy for Metastatic Cancer (Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.
5.Combining Targeted Therapies for Thoracic Cancers (Posted: 09/26/2006) - In this trial, patients with advanced thoracic cancers (cancers of the chest) or other cancers that have spread to the chest will be treated with the drugs romidepsin and flavopiridol. Researchers will study the safety of this combination and how these agents affect gene and protein expression in these patients.